PFK015 - Names and Identifiers
PFK015 - Physico-chemical Properties
Molecular Formula | C17H12N2O
|
Molar Mass | 260.29 |
Density | 1.237±0.06 g/cm3(Predicted) |
Boling Point | 464.4±45.0 °C(Predicted) |
Solubility | DMSO: 25.2 mg/mL |
Appearance | powder |
Color | white to beige |
pKa | 3.11±0.61(Predicted) |
Storage Condition | Sealed in dry,2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
In vitro study | PFK15 is capable of producing potent growth inhibition in a range of cancer cells. PFK15 also reduced F26BP, glucose uptake, and intracellular ATP levels in Jurkat T-cell leukemia cells and H522 lung adenocarcinoma cells. |
In vivo study | In vivo, PFK15 has appropriate pharmacokinetic properties. PFK15 (25 mg/kg, I. P.) inhibits the growth, metastatic spread and glucose metabolism of LLC tumors in homologous mice. In three human xenografted athymic cancer mouse models, PFK15 also produced anticancer effects similar to those of certified chemotherapeutic drugs. |
PFK015 - Risk and Safety
Hazard Symbols | Xi - Irritant
|
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin.
|
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
|
WGK Germany | 3 |
PFK015 - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 3.842 ml | 19.209 ml | 38.419 ml |
5 mM | 0.768 ml | 3.842 ml | 7.684 ml |
10 mM | 0.384 ml | 1.921 ml | 3.842 ml |
5 mM | 0.077 ml | 0.384 ml | 0.768 ml |
Last Update:2024-01-02 23:10:35
PFK015 - Introduction
PFK-015 is a compound whose full name is 2-amino -4-{4-[(2-methoxyethyl) amino]-6-[(4-methoxyphenyl) amino] pyrimidin-2-yl} p-oxybenzoic acid, the chemical formula of which is C? A? H? A N? A.
PFK-015 is a protein kinase inhibitor, mainly used in cancer treatment. It inhibits the growth and metabolism of tumor cells by inhibiting the activity of phosphofructokinase (PFKFB3). PFKFB3 is overexpressed in a variety of malignant tumor cells and is involved in the regulation of tumor energy metabolism and proliferation.
The method of preparing PFK-015 is more complicated and is generally synthesized by organic synthesis. Specific synthetic methods can refer to the relevant scientific literature and patents.
Regarding the safety of PFK-015, reasonable operation in a laboratory or clinical environment is required. Due to its role in protein kinases, there may be some toxicity and side effects. When using, it is necessary to follow the relevant safety procedures and wear personal protective equipment to ensure the safety of the experiment. In addition, in the process of using PFK-015, experiments should be carried out in strict accordance with relevant regulations and ethical guidelines.
Last Update:2024-04-10 22:29:15